title: Survival from early, intermediate, and late stages of HIV infection.
abstract: OBJECTIVE
  To estimate expected survival time among homosexual men infected with the human immunodeficiency virus type 1 (HIV-1) by (1) the calendar period before (1985-1988) and after (1989-1993) the widespread availability of acquired immunodeficiency syndrome (AIDS) treatments with antiretroviral and prophylactic interventions, and (2) stage of HIV disease.
  
  
  METHODS
  A prospective cohort study. A group of HIV-1-infected homosexual men were followed from July 1985 through June 1993 and evaluated every 6 months for the presence of clinical symptoms and measurement of the CD4 cell count. To measure the effectiveness of AIDS therapies in this nonrandomized study, we used 2 calendar periods as proxy measures of relative intensity of exposure to antiretroviral therapy. Stage of infection was defined by CD4 cell count and presence of HIV-related clinical symptoms or AIDS.
  
  
  METHODS
  Homosexual men infected with HIV-1 from the Multicenter AIDS Cohort Study.
  
  
  METHODS
  Survival time based on stage of HIV infection.
  
  
  RESULTS
  The percentage of HIV-1-infected individuals free of AIDS and clinical symptoms at baseline who survived 2.5 years according to baseline CD4 cell counts of 0 to 0.100, 0.101 to 0.200, and 0.201 to 0.350 x 10(9)/L was 22%, 53%, and 83%, respectively, for the 1985-1988 calendar period, compared with 54%, 71%, and 91%, respectively, for men in the 1989-1993 calendar period. Among men free of AIDS with CD4 cell counts of greater than 0.350 x 10(9)/L, the relative hazard of mortality was 1.6 to 2.3 times higher for those with clinical symptoms compared with those free of clinical symptoms.
  
  
  CONCLUSIONS
  Survival of AIDS-free HIV-1-infected individuals with CD4 cell counts of less than 0.350 x 10(9)/L has improved since antiretroviral and HIV prophylactic treatments have become available, but the long-term prognosis remains poor.
authors.affiliation: Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Md, USA.
authors.forename: C
authors.initials: C
authors.lastname: Enger
authors.forename: N
authors.initials: N
authors.lastname: Graham
authors.forename: Y
authors.initials: Y
authors.lastname: Peng
authors.forename: J S
authors.initials: JS
authors.lastname: Chmiel
authors.forename: L A
authors.initials: LA
authors.lastname: Kingsley
authors.forename: R
authors.initials: R
authors.lastname: Detels
authors.forename: A
authors.initials: A
authors.lastname: Muñoz
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000401:mortality* / Q000628:therapy; D015497:HIV-1; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis
chemical_list: D000998:Antiviral Agents